An analysis published in PLOS One on Wednesday by Toronto researchers gives the drug a closer look. The information comes from a clinical trial done in the 1970s that had been under the radar to the general public until recently, but was a major piece of the drug's approval, according to The Post. The main author of the analysis, Nav Persaud, MD, a researcher and family physician at St. Michael’s Hospital in Canada first took interest in this drug (which is sold as Diclectic in Canada) when a patient asked him whether it was a good idea to take it. “After she left, I was a little bit unsettled by the conversation,” Dr. Persaud told The Post. He had trouble finding basic information about the drug, and it took him years to try to answer the questions he had. In the end, he told The Post, he “found no good reason to prescribe this medication over others,” and so he no longer does.